The global preclinical imaging market size reached US$ 3.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.6 Billion by 2028, exhibiting a growth rate (CAGR) of 3.3% during 2023-2028. The growing demand for accurate and non-invasive imaging technologies, rising focus on personalized medicine and precise diagnostics to cater individual patient profiles, and increasing prevalence of various chronic diseases are some of the major factors propelling the market.
|Market Size in 2022
||US$ 3.7 Billion
|Market Forecast in 2028
||US$ 4.6 Billion
|Market Growth Rate (2023-2028)
Preclinical imaging refers to the advanced technology and methodologies used in the early stages of drug development and medical research. It involves non-invasive imaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and optical imaging, which allow researchers to visualize and analyze the structural and functional changes in living organisms. It assists in assessing the efficacy and safety of pharmaceutical compounds by providing insights into biological processes, disease progression, and the effects of potential treatments. As it aids in enhancing decision-making during drug development, the demand for preclinical imaging is increasing worldwide.
At present, the rising demand for more informed and successful research outcomes in healthcare facilities is contributing to the growth of the market. In line with this, the increasing need for enhanced imaging solutions to enhance the visualization of specific biological processes within living organisms is strengthening the growth of the market. Moreover, the growing demand for technologies that benefit in reducing risks and costs associated with later-stage failures is positively influencing the market. In addition, the rising emergence of hybrid imaging systems across the globe is offering lucrative growth opportunities to industry investors. Furthermore, technological advancements in imaging modalities, such as improved image resolution, sensitivity, and multi-modal capabilities, that allow researchers to gather intricate data on cellular and molecular levels are supporting the growth of the market. Besides this, rising investments in healthcare infrastructure around the world are bolstering the growth of the market.
Preclinical Imaging Market Trends/Drivers:
Rising demand for accurate and non-invasive imaging technologies
The rising demand for accurate and non-invasive imaging tools in early-stage drug development and disease research is contributing to the growth of the market. Besides this, the traditional methods often involve invasive procedures, which can impact study results and animal welfare. In line with this, the increasing adoption of advanced imaging modalities, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and optical imaging, addresses these challenges by enabling researchers to visualize and monitor biological processes in live subjects is supporting the growth of the market. This demand for accuracy and reduced invasiveness is not only vital for enhancing research outcomes but also aligns with ethical considerations in animal testing and research.
Increasing focus on personalized medicine and precise diagnostics
The increasing preference for personalized medicine, where treatments are tailored to individual patient profiles, is strengthening the growth of the market. Preclinical imaging allows researchers to gain insights into the specific characteristics and behaviors of diseases within different patient populations and enables the development of targeted therapies. In line with this, these imaging techniques aid in detecting diseases at their earliest stages, facilitating timely interventions, and potentially reducing healthcare costs, which is offering a favorable market outlook. Furthermore, the increasing demand for precise diagnostic tools for accurate early-stage disease detection is offering a favorable market outlook.
Growing prevalence of various chronic diseases
The rising adoption of preclinical imaging due to the increasing prevalence of numerous chronic diseases, such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders, among the masses across the globe is bolstering the growth of the market. People are increasingly affected by these diseases due to various factors, such as aging populations, sedentary lifestyles, poor dietary habits, and environmental factors. In addition, these imaging solutions play a crucial role in addressing this challenge by providing insights into disease progression and potential treatment strategies. Researchers utilize advanced imaging modalities to study disease models, monitor changes in organ structures, and evaluate the effects of experimental therapies. This proactive approach enables early disease detection, assessment of treatment efficacy, and optimization of therapeutic interventions.
Preclinical Imaging Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global preclinical imaging market report, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product and end use.
Breakup by Product:
- Optical Imaging Systems
- Preclinical Nuclear Imaging Systems
- Micro-Ultrasound Systems
- Micro-MRI Systems
- Micro-CT Systems
- Preclinical Photoacoustic Imaging Systems
- Preclinical Magnetic Particle Imaging (MPI) Systems
- Preclinical Optical Imaging Systems
- Preclinical Nuclear Imaging Reagents
- Preclinical MRI Contrast Agents
- Preclinical Ultrasound Contrast Agents
- Preclinical CT Contrast Agents
The report has provided a detailed breakup and analysis of the market based on the product. This includes modality (optical imaging systems, preclinical nuclear imaging systems, micro-ultrasound systems, micro-MRI systems, micro-CT systems, preclinical photoacoustic imaging systems, and preclinical magnetic particle imaging (MPI) systems) and reagent (preclinical optical imaging systems, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents).
Modality plays a crucial role in providing accurate imaging analysis through magnetic resonance imaging (MRI), computed tomography (CT), and optical imaging. The magnetic resonance imaging (MRI) offers high-resolution anatomical and functional imaging that allows researchers to visualize tissue structures and physiological processes. In addition, computed tomography (CT) provides detailed three-dimensional (3D) images of internal structures that aid in precise anatomical assessment and disease visualization. Apart from this, optical imaging is an innovative technique that utilizes light to visualize and analyze biological processes within living organisms. This non-invasive imaging method employs bioluminescence and fluorescence to highlight specific cellular and molecular activities in real-time.
Preclinical nuclear imaging reagents are specialized substances used in conjunction with nuclear imaging techniques, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), to enhance the visualization and quantification of specific biological processes within living organisms. Besides this, preclinical ultrasound contrast agents are specialized substances designed to enhance the visibility and clarity of ultrasound images during preclinical research. It relies on sound waves to create images of internal structures, and contrast agents improve the differentiation between tissues or enhance the visualization of specific areas.
Breakup by End Use:
- Biotech Companies
- Pharmaceutical Companies
- Research Institutes
Biotech companies account for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the end use. This includes biotech companies, pharmaceutical companies, and research institutes. According to the report, biotech companies represented the largest segment. Biotech companies utilize preclinical imaging for a wide range of applications, such as drug discovery, target validation, and efficacy assessments. These companies leverage advanced imaging modalities and reagents to study disease mechanisms, screen potential drug candidates, and optimize treatment regimens. Preclinical imaging enables biotech firms to make informed decisions during early-stage research and development and increases the chances of successful drug candidates reaching clinical trials.
Pharmaceutical companies rely on preclinical imaging to expedite drug development processes. By using imaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT), these companies gain insights into drug pharmacokinetics, biodistribution, and therapeutic effects. It also aids in assessing drug safety, optimizing dosing regimens, and predicting clinical outcomes. Pharmaceutical firms employ imaging technologies to streamline decision-making, reduce development costs, and enhance the overall success rates of new drugs.
Research institutes play a pivotal role in advancing scientific knowledge across various disciplines. These institutes conduct fundamental research to unravel disease mechanisms, study genetic pathways, and investigate novel therapeutic interventions. Preclinical imaging assists researchers in understanding complex biological processes, facilitating discoveries that underpin advancements in medicine and healthcare.
Breakup by Region:
- North America
- United Kingdom
- Asia Pacific
- South Korea
- Latin America
- Middle East and Africa
North America exhibits a clear dominance, accounting for the largest preclinical imaging market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share due to the presence of well-established healthcare and life sciences ecosystem. In line with this, the rising focus on personalized medicine among individuals and healthcare facilities is bolstering the growth of the market in the region. Apart from this, increasing advancements in precision diagnostics, along with the rising demand for accurate and comprehensive imaging solutions, is contributing to the growth of the market. In addition, favorable government policies are supporting the growth of the market in the region.
Major players are developing enhanced imaging modalities, reagents, and software solutions. This includes enhancing imaging resolution, sensitivity, and multi-modal capabilities, and improving data analysis and interpretation tools. In line with this, companies are exploring new applications for these imaging solutions beyond traditional drug development. This includes expanding into fields, such as neuroscience, cardiology, and oncology, that broaden the potential use cases for their imaging technologies. Apart from this, various manufacturers are recognizing the importance of advanced software tools for data analysis and interpretation. In addition, they are developing user-friendly software platforms that enable researchers to extract meaningful insights from complex imaging data.
The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
- Aspect Imaging Ltd.
- AXT PTY LTD
- Bruker Corporation
- FUJIFILM Visualsonics, Inc. (Fujifilm Holdings Corporation)
- LI-COR Biosciences
- Mediso Ltd.
- MILabs B.V. (Rigaku Corporation)
- MR Solutions Ltd.
- PerkinElmer, Inc.
- Photon etc.
- TriFoil Imaging
Preclinical Imaging Market Report Scope:
|Base Year of the Analysis
| Historical Period
|Scope of the Report
||Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
- Modality: Optical Imaging Systems, Preclinical Nuclear Imaging Systems, Micro-Ultrasound Systems, Micro-MRI Systems, Micro-CT Systems, Preclinical Photoacoustic Imaging Systems, Preclinical Magnetic Particle Imaging (MPI) Systems
- Reagent: Preclinical Optical Imaging Systems, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, Preclinical CT Contrast Agents
|End Uses Covered
||Biotech Companies, Pharmaceutical Companies, Research Institutes
||Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Aspect Imaging Ltd., AXT PTY LTD, Bruker Corporation, FUJIFILM Visualsonics, Inc. (Fujifilm Holdings Corporation), LI-COR Biosciences, Mediso Ltd., MILabs B.V. (Rigaku Corporation), MR Solutions Ltd., PerkinElmer, Inc., Photon etc., TriFoil Imaging, etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global preclinical imaging market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global preclinical imaging market?
- What is the impact of each driver, restraint, and opportunity on the global preclinical imaging market?
- What are the key regional markets?
- Which countries represent the most attractive preclinical imaging market?
- What is the breakup of the market based on the product?
- Which is the most attractive product in the preclinical imaging market?
- What is the breakup of the market based on the end use?
- Which is the most attractive end use in the preclinical imaging market?
- What is the competitive structure of the global preclinical imaging market?
- Who are the key players/companies in the global preclinical imaging market?
Key Benefits for Stakeholders:
- IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the preclinical imaging market from 2017-2028.
- The research study provides the latest information on the market drivers, challenges, and opportunities in the global preclinical imaging market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the preclinical imaging industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.